NCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
Providence Health & Services
Melanoma and Skin Cancer Trials Limited
Novartis
Emory University
Advanced Accelerator Applications
Grupo Espanol de Tumores Neuroendocrinos